Is Melanotan Dangerous?

There is no controlled safety data on Melanotan at all — not one trial designed to find out what it does to people over time — and the case-report literature that stands in its place points consistently in one direction: moles that change and multiply, melanoma diagnosed in people who had used it, and acute effects including nausea, flushing and prolonged spontaneous erection 1234. That combination of an empty column where the safety evidence should be and a uniform signal in the literature that filled the gap is why medicines regulators in several countries have issued public warnings about it.

That is a less satisfying answer than either of the confident ones. Nobody can tell you how dangerous it is, because the studies that would produce a number were never run. What can be said is that everything published about it is unfavourable, and that no counterbalancing literature exists.

What is Melanotan?

A synthetic analogue of alpha-melanocyte-stimulating hormone — the body's own signal to the pigment cells in skin — engineered to be considerably more potent than the natural hormone and to resist being broken down as quickly 4. The name covers more than one compound, but Melanotan II is the version most of the published safety literature concerns.

The detail that explains almost everything else is that it is not selective. The hormone system it imitates runs through a family of five melanocortin receptors, spread across skin, brain, adrenal tissue and elsewhere, involved between them in pigmentation, appetite, sexual function, inflammation and cardiovascular regulation 1. A compound that activates one of those affects pigmentation. A compound that does not discriminate between them affects several systems at once.

That reframes the reported effects. The tan, the nausea and the erections are not one wanted effect plus two unrelated side effects that happen to arrive together. They are a single pharmacology showing up in different tissues.

Has it been tested in people?

Once, briefly, about thirty years ago. A pilot phase-I study published in 1996 evaluated the peptide in a small group of subjects, confirmed measurable pigment change, and recorded the acute effects that recur throughout the later literature — nausea, flushing and spontaneous erection 4. Development as a licensed medicine did not continue. Nothing resembling a safety programme has been published since.

Be precise about what a study of that kind establishes. A small pilot shows a compound is pharmacologically active in humans and gives a first impression of short-term tolerability. That is a real result, and it is all it is.

What it cannot do is detect an adverse event rarer than roughly one in the number enrolled, characterise anything developing over years rather than days, or address cancer risk — which, for a compound whose purpose is to stimulate pigment cells, is the question that matters most. Everything known about longer-term effects comes from clinicians writing up patients who turned up in their clinics.

What has actually been reported?

The documented signals are dermatological, gastrointestinal, urological and — least obviously, most importantly — diagnostic. Reported only as the papers report them:

• Eruptive melanocytic naevi — new moles appearing in unusual numbers.
• Existing moles darkening, enlarging or changing outline within weeks to months.
• Melanoma diagnosed in people with a documented history of use, published as individual cases.
• Nausea, sometimes with vomiting, and facial flushing.
• Spontaneous penile erection, extending in some reports to priapism — a urological emergency, because a sustained erection starves the tissue of oxygen.
• Skin darkening without ultraviolet exposure: the effect people seek, and a diagnostic problem.

The best-characterised skin finding is the eruptive naevi. Case reports describe new moles appearing in numbers and at a pace unusual for the patient's age, alongside existing moles that darkened, grew or changed shape 2. Mechanistically this is not a surprise: melanocortin agonism is a direct stimulus to pigment cells, and moles are collections of pigment cells. Visible change in them is the compound doing what it does.

The more serious reports concern melanoma diagnosed in people using it, which exists in the peer-reviewed dermatological literature as individual cases rather than a series or a study 3. A review of the risks of unregulated use of these analogues collects them alongside the wider signal set 1. The number of published cases is small — and, because nobody knows how many people have ever been exposed, it cannot be turned into a rate.

The acute effects are the most consistently reported and, on their own, the least alarming. Nausea and flushing appear in the original pilot work 4 and throughout the review literature 1. Spontaneous erection is reported reliably enough to read as a predictable consequence of the same receptor activity rather than an oddity.

Do case reports prove it causes melanoma?

No — and it is worth holding both halves of this rather than picking the convenient one. A case report describes what happened to one patient. It shows that two things occurred in sequence, documents a phenomenon clearly enough for others to recognise it, and generates a hypothesis. It cannot establish causation, because it has no control group and no denominator — no count of how many exposed people did not develop the outcome.

There is a specific confounder here too, and it should be stated rather than glossed over. People who go looking for a tanning compound are plausibly at higher baseline melanoma risk anyway: sun-seeking behaviour, sunbed use, high cumulative ultraviolet exposure, and the fair skin types that make a natural tan hard to achieve and therefore desirable to pursue. A group at elevated risk produces melanoma cases whether or not any particular exposure contributed.

Now the other half, stated just as plainly. There is no controlled data on this compound: no cohort study, no exposure registry, no long-term follow-up, no post-marketing surveillance — because none of the structures that generate those apply to something distributed outside medical regulation. So the case literature is not merely the weakest evidence available. It is the only safety evidence that exists, and its direction is uniform: no reports of moles settling down, no reassuring long-term series, no counterweight of any kind.

Two readings are available and both should be refused. The first dismisses the case literature because case reports cannot prove causation — treating a limitation as a refutation, and handing the benefit of the doubt to a compound nobody has tested. The second reads that literature as having demonstrated that Melanotan causes melanoma, which it has not. The accurate position sits between them, and it is not a comfortable middle: a plausible mechanism, a consistent and unfavourable set of observations, a confounder that cannot be excluded, and nothing capable of settling it.

Why is the tanning effect itself a problem?

Because early melanoma detection is almost entirely visual, and every visual criterion is a comparison. A lesion is judged against the skin around it, against the other lesions on the same body, and — the strongest of the three — against how it looked the last time anyone examined it. Asymmetry, uneven colour, size relative to neighbours, change over time: none is a property of a lesion in isolation. Each is a difference from a reference.

A compound that darkens the whole skin surface while also darkening and multiplying moles degrades all three comparisons at once. Background contrast falls, so a lesion stands out less. Uneven colour is harder to judge against uniformly deepened pigment. Change — the criterion carrying most diagnostic weight — turns genuinely ambiguous, because a mole that has darkened may be responding to melanocortin stimulation or may be evolving into something else, and looking cannot separate the two. New moles in quantity add lesions to track and a ready benign explanation for each.

This is a separate claim from the one about melanoma risk, and it stands on its own. Even if the compound turned out to promote nothing at all, it would still interfere with the process by which melanoma gets caught while it is treatable. That follows from how detection works.

Is Melanotan legal?

It is not an approved medicine in the United States, the United Kingdom or the European Union, and has never been licensed for human use in any of them. Where it circulates, it is supplied as a laboratory research chemical — a category carrying no assessment of human safety, no approved indication, and no quality requirements comparable to those for medicines.

Several national medicines regulators have gone further than silence and issued public warnings about unlicensed melanotan products sold to consumers. "Not approved" and "proven harmful" are different findings, and it is the first that applies here — but unapproved status is not a neutral fact either. It means no independent body has ever examined a safety dossier, because none was ever submitted.

Is the prescription melanocortin medicine the same thing?

No. Bremelanotide is a related but distinct compound that went down the other road entirely: preclinical characterisation, randomised controlled trials against defined endpoints, regulatory review, and approval for one narrow indication. Different molecule, different evidence, different status. Shared chemical ancestry transfers none of it across.

The point is not that one molecule is virtuous and the other wicked. It is that one has been characterised and the other has not — a difference in knowledge before it is a difference in pharmacology. Reasoning from "a similar compound is a licensed medicine" to "this one is probably fine" skips the only step that ever produced the reassurance.

So is Melanotan dangerous?

The honest answer is that the question has never been asked in a form capable of answering it, and that everything published leans one way. That is neither a dodge nor a verdict. It is an accurate description of an evidence base consisting of one small study from the 1990s and a scattering of case reports by dermatologists who did not like what they were seeing.

What can be stated without hedging: there is no controlled safety data; the compound acts on several receptor systems at once, so its effects were never going to stay confined to skin colour; the published skin findings are coherent with that mechanism rather than mysterious; and the pigmentation interferes with how melanoma is detected, whether or not it influences melanoma risk.

What cannot be stated is how often any of it happens, or in whom. Those numbers do not exist and cannot be reconstructed, because the studies that would generate them were never commissioned. An absence of data is not a clean safety record — it is an absence, and on a compound that stimulates the cells melanoma arises from, it is the most uncomfortable kind there is.